人脑胶质瘤中CyclinD1和PCNA联合检测与肿瘤分级及患者预后相关性研究

目的 探讨细胞周期素D1(CyclinD1)和增殖细胞核抗原(PCNA)在脑胶质瘤中的联合检测与该肿瘤恶性程度及患者预后的相关性.方法 采用免疫组化SP法联合检测63例脑胶质瘤组织中CyclinD1和PCNA表达水平,并行临床随访,对比分析脑胶质瘤不同病理分级和不同生存期组间CyclinD1和PCNA单独检测标记指数(LI)及联合检测LI的差异.结果 PCNA和CyclinD1联合检测LI随着脑胶质瘤恶性程度的增高而增大,各级别间联合检测LI的差异均有显著性(P<0.05).同时该联合检测LI随着脑胶质瘤患者生存期限的延长而减少,不同生存期组问的联合检测LI均有显著性差异(P<0.05).结论 CyclinD1和PCNA联合检测LI较PCNA或CyclinD1单独检测LI能更为准确地反映脑胶质瘤恶性程度及患者预后,可作为评估脑胶质瘤恶性程度及患者预后的辅助指标.

Coexpression of CyclinD1 and PCNA in gliomas and its correlation with glioma pathological grades and prognosis

Objective To investigate the coexpression of CyclinD1 and proliferating cell nuclear antigen (PCNA) in gliomas and find out its correlation with glioma pathological grades and prognosis. Methods SP immunohistochemical method was used to detect the coexpression of CyclinD1 and PCNA in 63 patients with glioma. All cases were followed up. The labeling index (LI) of CyclinD1 or/and PCNA was compared in different glioma pathological grades and survival periods.Results The LI of CyclinD1 and PCNA was increased with the increase of glioma grades, and there were significant differences among different glioma grades (P＜0.05). While the LI of CyclinD1 and PCNA was decreased with the prolonging of survival period, and there were significant differences among different survival periods (P＜0.05). Conclusions The LI of CyclinD1 and PCNA is more accurate than the one of CyclinD1 or PCNA alone when used for evaluating glioma grades and prognosis,so it can be a diagnostic index for the evaluation of glioma grades and prognosis.